Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Soliris
Pharma
With biosim sales up 16%, Amgen expects another boost in 2025
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion by the end of the decade.
Kevin Dunleavy
Feb 5, 2025 11:28am
Argenx's Vyvgart holds its own against AZ's rare disease duo
Jul 25, 2024 3:16pm
Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch
May 29, 2024 10:26am
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
Novartis gains first FDA approval for touted blood disorder drug
Dec 6, 2023 11:02am